Literature DB >> 7601350

Developmental control of the G1 to S transition in Drosophila: cyclin Eis a limiting downstream target of E2F.

R J Duronio1, P H O'Farrell.   

Abstract

The E2F transcription factor is required for S phase in Drosophila. While it also triggers expression of replication genes at the G1-S transition, the relevance of this transcription is not clear because many of the induced gene products are sufficiently stable that new expression is not required for S phase. However, one unstable product could couple S phase to E2F activation. Here we show that cyclin E expression at G1-S requires E2F, that activation of E2F without cyclin E is not sufficient for S phase, and that early in G1 ectopic expression of cyclin E alone can bypass E2F and induce S phase. We conclude that cyclin E is the downstream gene that couples E2F activity to G1 control. Not all embryonic cycles are similarly coupled to E2F activation, however. The rapidly proliferating CNS cells, which exhibit no obvious G1, express cyclin E constitutively and independently to E2F. Instead, cyclin E expression activates E2F in the CNS. Thus, this tissue-specific E2F-independent transcription of cyclin E reverses the hierarchical relationship between cyclin E and E2F. Both hierarchies activate expression of the full complement of replication functions controlled by E2F; however, whereas inactivation of E2F can produce a G1 when cyclin E is downstream of E2F, we propose that an E2F-independent source of E eliminates G1.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7601350     DOI: 10.1101/gad.9.12.1456

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  94 in total

1.  CDC25A phosphatase is a target of E2F and is required for efficient E2F-induced S phase.

Authors:  E Vigo; H Müller; E Prosperini; G Hateboer; P Cartwright; M C Moroni; K Helin
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

2.  Involvement of Myc activity in a G(1)/S-promoting mechanism parallel to the pRb/E2F pathway.

Authors:  E Santoni-Rugiu; J Falck; N Mailand; J Bartek; J Lukas
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

Review 3.  The G1 restriction point as critical regulator of neocortical neuronogenesis.

Authors:  V S Caviness; T Takahashi; R S Nowakowski
Journal:  Neurochem Res       Date:  1999-04       Impact factor: 3.996

4.  E2F mediates developmental and cell cycle regulation of ORC1 in Drosophila.

Authors:  M Asano; R P Wharton
Journal:  EMBO J       Date:  1999-05-04       Impact factor: 11.598

5.  Timing of cyclin E gene expression depends on the regulated association of a bipartite repressor element with a novel E2F complex.

Authors:  L Le Cam; J Polanowska; E Fabbrizio; M Olivier; A Philips; E Ng Eaton; M Classon; Y Geng; C Sardet
Journal:  EMBO J       Date:  1999-04-01       Impact factor: 11.598

Review 6.  Integration of the pRB and p53 cell cycle control pathways.

Authors:  C L Stewart; A M Soria; P A Hamel
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

7.  Mutations in Drosophila DP and E2F distinguish G1-S progression from an associated transcriptional program.

Authors:  I Royzman; A J Whittaker; T L Orr-Weaver
Journal:  Genes Dev       Date:  1997-08-01       Impact factor: 11.361

8.  Pan-neural Prospero terminates cell proliferation during Drosophila neurogenesis.

Authors:  L Li; H Vaessin
Journal:  Genes Dev       Date:  2000-01-15       Impact factor: 11.361

9.  Distinct mechanisms of E2F regulation by Drosophila RBF1 and RBF2.

Authors:  Olivier Stevaux; Dessislava Dimova; Maxim V Frolov; Barbie Taylor-Harding; Erick Morris; Nicholas Dyson
Journal:  EMBO J       Date:  2002-09-16       Impact factor: 11.598

10.  Cyclins E1 and E2 are required for endoreplication in placental trophoblast giant cells.

Authors:  Tiziana Parisi; Andreas R Beck; Nathalie Rougier; Tom McNeil; Linda Lucian; Zena Werb; Bruno Amati
Journal:  EMBO J       Date:  2003-09-15       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.